Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor website, with a replay available afterward. This event is important for investors and the public to understand Lilly's progress in its pharmaceutical innovations and financial health. The company continues to focus on advancing treatments for diabetes, obesity, Alzheimer's, immune disorders, and cancer.
As investors await Eli Lilly's third-quarter 2026 financial results announcement on October 29, the company's stock is currently trading at USD 1,258.04 on Pluang as of October 15, 2026, 21:14 WIB. The stock has gained 3.85% in the past day and holds a market capitalization of $1.08 trillion. Despite strong recent gains, Pluang order activity shows a majority of 80% Sell orders compared to 20% Buy, reflecting varied investor sentiment.
New data from Eli Lilly reveal that Omvoh (mirikizumab-mrkz) effectively achieves comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year of treatment. These outcomes, observed even...
Sangamo Therapeutics has initiated an auction process for its ST-503 program, a clinical-stage treatment targeting chronic neuropathic pain from small fiber neuropathy, with completion expected in Q4 2026. The program has FDA Fast Track status and sh...
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
